in two forms-as a kit for reconstitution using a Ga 68 generator and as Netspot Injection, a ready-to-use dose delivered from a local radiopharmacy in selected metropolitan areas. The company says it intends to sell the product in the U.S. NETSPOT ® SOMAKIT TOC ® GLUSCAN / BARNASCAN. “Netspot provides another diagnostic tool whose results will help clinicians determine the location and extent of the tumor.”Īdvanced Accelerator Applications, headquartered in France, says the product will be made available to the U.S. ![]() “Use of advanced imaging techniques to detect rare neuroendocrine tumors at an early stage in patients is critical,” FDA director of medical imaging products Libero Marzella, MD, PhD, says in prepared remarks. These tumors have receptors for somatostatin, a hormone that regulates the endocrine system, and Ga 68 dotatate works by binding to such receptors. Advanced Accelerator Applications and requires use of a GMP Ge-68/Ga-68 generator. The agency explains that NETs are rare benign or malignant tumors that develop in the hormone-producing cells of the neuroendocrine system. Gallium 68 NETSPOT, an FDA approved PET drug used for neuroendocrine. ![]() Marketed by Advanced Accelerator Applications, the kit, to be called Netspot, represents the first clinical application of the radioactive probe drug Ga 68 dotatate, according to FDA. Food and Drug Administration has approved a kit used to prepare and inject a PET imaging agent that can ferret out rare somatostatin receptor-positive neuroendocrine tumors (NETs) in adult and pediatric patients.
0 Comments
Leave a Reply. |